Szerző szerinti böngészés "Alimohammadi, Shahrzad (1991-) (Gyógyszerész)"
Megjelenítve 1 - 2 (Összesen 2)
Találat egy oldalon
Rendezési lehetőségek
Tétel Szabadon hozzáférhető Cancer recurrence or aggravation following COVID-19 vaccinationSoleimani, Parisa; Yadollahifarsani, Sepideh; Motieian, Mahsa; Chenarani Moghadam, Mahshid Sadat; Alimohammadi, Shahrzad; Khayyat, Azadeh; Esmaeil Pour, Mohammad Ali; Neshat, Sina; Marashi, Narges Alsadat; Mahmoodnia, Leila; Masomi, Rohollah; Alimohammadi, Shahrzad (1991-) (Gyógyszerész); Alimohammadi, Shahrzad (1991-) (Gyógyszerész); Immunológiai Intézet -- 18; ÁOK; Debreceni Egyetem; Debreceni Egyetem - Molekuláris Orvostudomány Doktori IskolaCOVID-19 infection has been a global health issue in the past recent years and numerous topics are studied in order to discover its pathophysiology and potential side effects. The potential for disease recurrence following the administration of the COVID-19 vaccine is one of the issues that has recently attracted attention. Several studies have revealed that the COVID-19 vaccines, like other vaccines, may have side effects and, in some cases, they may even deteriorate the underlying illnesses, such as rheumatic diseases, autoimmune diseases, and cancers. The effectiveness and safety of the COVID-19 vaccine for patients with malignancies are one of the factors that are considered regarding this vaccine. Lymph node involvement, disease recurrence, and potential paraclinical changes after receiving the COVID-19 vaccine are some of the concerns of patients with malignancy. In this mini-review, we attempted to investigate cases of cancer recurrence or recovery as well as lymphadenopathy following vaccination.Tétel Szabadon hozzáférhető Targeted-release budesonide in immunoglobulin A nephropathy; a mini-reviewToumaj, Shiva; Alimohammadi, Shahrzad; Ghasemi, Maryam; Shayanpour, Shokouh; Alimohammadi, Shahrzad (1991-) (Gyógyszerész); Alimohammadi, Shahrzad (1991-) (Gyógyszerész); Immunológiai Intézet -- 18; ÁOK; Debreceni Egyetem; Debreceni Egyetem - Molekuláris Orvostudomány Doktori IskolaImmunoglobulin A nephropathy is the most common kind of primary glomerulonephritis worldwide and one of the main causes of renal failure. Systemic corticosteroid therapy may protect against renal deterioration in IgA nephropathy; however, it is not often advised for long-term treatment due to possible side effects. Recent studies present promising results of the new targeted-release formulation of budesonide that delivers the drug to the distal ileum to reduce side effects for patients with IgA nephropathy. In this paper, we highlighted the potential benefits of budesonide as a treatment option for IgA nephropathy and the need for additional studies to confirm its effectiveness. The lack of alternative treatments to prevent renal deterioration without other systemic side effects motivated us to gather relevant information to fill this gap. In this brief overview, we have reviewed some of the most recently published studies regarding how budesonide protects against IgA nephropathy. Studies reveal that budesonide might significantly decrease proteinuria, hematuria, and creatinine level while maintaining normal renal function. Though, a limited number of trials have been established to date, and further investigations are needed to confirm the benefit of the new targeted-release budesonide in treating IgA nephropathy